Invert, a leader in AI-driven bioprocess software, has unveiled Invert Assist, an AI-powered analysis interface designed to transform how biopharmaceutical developers and manufacturers work with complex bioprocess data. The new tool enables users to conduct advanced data analysis and process modeling using natural language prompts, marking a significant advancement in accelerating the development and manufacturing of life-saving therapies. Biopharmaceutical companies face persistent challenges in extracting value from vast and fragmented bioprocess data. Upstream and downstream data are often siloed across departments, scales, and facilities, hampered by limited analyst time, rigid IT systems, and disjointed workflows. These issues are compounded by the rise of complex therapeutic modalities like cell and gene therapies, which demand deeper insights and more sophisticated process understanding. This leads to an “analysis to action” gap—where data sits unused, delaying innovation and reducing manufacturing efficiency. Invert Assist directly tackles this gap by turning raw bioprocess data into immediate, actionable insights. With a simple chat interface, users can ask questions such as “What factors caused yield differences between batch runs?” or “Predict the impact of temperature shifts in the bioreactor.” The system automatically detects trends, identifies root causes, builds predictive models, runs simulations, and summarizes key findings across unit operations—from cell culture to purification—without requiring users to write code. “We built Invert to close the gap between data and action,” said Martin T. Permin, CEO and Founder of Invert. “Invert Assist is the next evolution: transforming bioprocess data into decisions in seconds, not months. It’s not just faster—it’s smarter, more accurate, and built for the real world of biomanufacturing.” Internal evaluations show Invert Assist significantly outperforms general-purpose large language models like OpenAI’s ChatGPT on bioprocess-specific tasks. Using custom benchmarks tailored to real bioprocess challenges, Invert Assist delivered recommendations for process optimization that scored over two times higher than those from generic models. This superior performance stems from its foundation in Invert’s proprietary bioprocess software, which unifies, harmonizes, and contextualizes data across scales and sites. Unlike many AI tools, Invert Assist operates securely within regulated manufacturing environments. It executes fully traceable and verifiable Python code, ensuring compliance with industry standards. The system is designed from the ground up for biomanufacturing, leveraging decades of frontline bioprocess expertise to solve real-world problems—from lab bench to production floor. “Invert Assist was built with our core strengths in mind: domain-specific knowledge, deep industry experience, and AI-ready data,” said Permin. “That’s why we’re confident in calling it the first AI system purpose-built for bioprocess.” Invert’s cloud-native platform enables seamless integration into existing workflows, empowering scientists and engineers to unlock critical insights faster and drive innovation at scale. By turning data into decisions in real time, Invert Assist helps accelerate time-to-milestone across the biopharmaceutical lifecycle. For more information about Invert Assist, visit https://invertbio.com/assist. Media Contact: Emily Nault, Senior VP Commercial, [email protected]